LIfT BioSciences Welcomes Immunotherapy Veteran Mark Exley as New CSO

LIfT BioSciences has announced the appointment of Dr. Mark A. Exley as Chief Scientific Officer, effective April 7, 2025. Known for his deep scientific insight and leadership in immuno-oncology, Exley steps into this key role as LIfT readies its pioneering neutrophil-based cell therapy for clinical trials. With over 30 years of experience driving R&D from discovery through late-stage clinical programs, Exley brings a rare blend of academic excellence and biotech know-how to the team.

His resume includes pivotal leadership roles at Imvax Inc. and MiNK Therapeutics, as well as a long-standing advisory presence in immunotherapy innovation. Exley’s appointment marks a significant milestone in LIfT’s journey to transform cancer treatment through its Neutrophil-based Leukocyte Infusion Therapy (N-LIfT) platform—an approach aiming to restore immune function and counter tumour resistance. The company sees this as a turning point in bringing its vision closer to patients in need.